An exploratory correlative biomarker analysis of NSABP FB-7, a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel plus neratinib or trastuzumab or neratinib and trastuzumab followed by doxorubicin and cyclophosphamide with postoperative trastuzumab in women with locally advanced HER2-positive breast cancer

Patrick Gavin,1 Phillip Kim,2 Corey Lipchik,1 Emma Langley,2 Huichen Feng,1 Gary Meyer,2 S. Rim Kim,1 Joseph Michel,1 Samuel Jacobs,1 Ashok Srinivasan,1 Kay Pogue-Gelle1

1NSABP Foundation, Inc., Pittsburgh, PA; 2Pierian Biosciences, San Diego, CA

This presentation is the intellectual property of the author/presenter. Contact samuel.jacobs@nsabp.org for permission to reprint and/or distribute.

An exploratory correlative biomarker analysis of NSABP FB-7, a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel plus neratinib or trastuzumab or neratinib and trastuzumab followed by doxorubicin and cyclophosphamide with postoperative trastuzumab in women with locally advanced HER2-positive breast cancer

Patrick Gavin,1 Phillip Kim,2 Corey Lipchik,1 Emma Langley,2 Huichen Feng,1 Gary Meyer,2 S. Rim Kim,1 Joseph Michel,1 Samuel Jacobs,1 Ashok Srinivasan,1 Kay Pogue-Gelle1

1NSABP Foundation, Inc., Pittsburgh, PA; 2Pierian Biosciences, San Diego, CA

This presentation is the intellectual property of the author/presenter. Contact samuel.jacobs@nsabp.org for permission to reprint and/or distribute.

An exploratory correlative biomarker analysis of NSABP FB-7, a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel plus neratinib or trastuzumab or neratinib and trastuzumab followed by doxorubicin and cyclophosphamide with postoperative trastuzumab in women with locally advanced HER2-positive breast cancer

Patrick Gavin,1 Phillip Kim,2 Corey Lipchik,1 Emma Langley,2 Huichen Feng,1 Gary Meyer,2 S. Rim Kim,1 Joseph Michel,1 Samuel Jacobs,1 Ashok Srinivasan,1 Kay Pogue-Gelle1

1NSABP Foundation, Inc., Pittsburgh, PA; 2Pierian Biosciences, San Diego, CA

This presentation is the intellectual property of the author/presenter. Contact samuel.jacobs@nsabp.org for permission to reprint and/or distribute.

An exploratory correlative biomarker analysis of NSABP FB-7, a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel plus neratinib or trastuzumab or neratinib and trastuzumab followed by doxorubicin and cyclophosphamide with postoperative trastuzumab in women with locally advanced HER2-positive breast cancer

Patrick Gavin,1 Phillip Kim,2 Corey Lipchik,1 Emma Langley,2 Huichen Feng,1 Gary Meyer,2 S. Rim Kim,1 Joseph Michel,1 Samuel Jacobs,1 Ashok Srinivasan,1 Kay Pogue-Gelle1

1NSABP Foundation, Inc., Pittsburgh, PA; 2Pierian Biosciences, San Diego, CA

This presentation is the intellectual property of the author/presenter. Contact samuel.jacobs@nsabp.org for permission to reprint and/or distribute.

An exploratory correlative biomarker analysis of NSABP FB-7, a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel plus neratinib or trastuzumab or neratinib and trastuzumab followed by doxorubicin and cyclophosphamide with postoperative trastuzumab in women with locally advanced HER2-positive breast cancer

Patrick Gavin,1 Phillip Kim,2 Corey Lipchik,1 Emma Langley,2 Huichen Feng,1 Gary Meyer,2 S. Rim Kim,1 Joseph Michel,1 Samuel Jacobs,1 Ashok Srinivasan,1 Kay Pogue-Gelle1

1NSABP Foundation, Inc., Pittsburgh, PA; 2Pierian Biosciences, San Diego, CA

This presentation is the intellectual property of the author/presenter. Contact samuel.jacobs@nsabp.org for permission to reprint and/or distribute.